Like writing these ridiculously long responses
10.2174/1381612824666180614082950 [DOI] [PubMed] [Google Scholar] Kato N., Kawai T., Maeda H., Nagao T., Murakami H., Miyazawa K., et al
IGF-1, as happens with other hormone therapies (thyroid hormone or insulin), should never been used lightly without firstly assessing its deficiency (local, central or systemic) and secondly by ascertaining that no tumours are near to be generated
One thing for certain is that demand is not slowing down
Examining specific fracture sites revealed non-significantly reduced risk of fractures of the humerus and of the spine with GLP-1 RAs compared to DPP-4is
The case for evening injections Evening injectors have their own arguments